{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T20:44:07Z","timestamp":1775940247498,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.urology.2018.03.038","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T07:50:23Z","timestamp":1523001023000},"page":"115-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Mirabegron 25\u2009mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction"],"prefix":"10.1016","volume":"117","author":[{"given":"Chun-Hou","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2018.03.038_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2018.03.038_bib0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.urology.2018.03.038_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2018.03.038_bib0025","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2018.03.038_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urols.2014.12.007","article-title":"Perspectives on mirabegron in the treatment of overactive bladder syndrome: a new beta-3 adrenoceptor agonist","volume":"26","author":"Kuei","year":"2015","journal-title":"Urol Sci"},{"issue":"suppl 6","key":"10.1016\/j.urology.2018.03.038_bib0035","first-page":"S3","article-title":"Bladder outlet obstruction: etiology and evaluation","volume":"7","author":"Dmochowski","year":"2005","journal-title":"Rev Urol"},{"key":"10.1016\/j.urology.2018.03.038_bib0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ijcp.12488","article-title":"How to choose first-line treatment for men with predominant storage lower urinary tract symptoms: a prospective randomised comparative study","volume":"69","author":"Liao","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2018.03.038_bib0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2018.03.038_bib0050","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.03.038_bib0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.03.038_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/luts.12091","article-title":"Urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder","volume":"8","author":"Wada","year":"2016","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2018.03.038_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12894-016-0165-3","article-title":"The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with \u03b11-adrenergic receptor blocker monotherapy: prospective analysis of elderly men","volume":"16","author":"Matsuo","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2018.03.038_bib0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/nau.22388","article-title":"Rationalization of interpretation of uroflowmetry for a non-Caucasian (Indian) population: conceptual development and validation of volume-normalized flow rate index","volume":"33","author":"Agarwal","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2018.03.038_bib0075","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/nau.10034","article-title":"Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats","volume":"21","author":"Takeda","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2018.03.038_bib0080","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.urology.2015.06.025","article-title":"Acute urinary retention rates in the general male population and in adult men with lower urinary tract symptoms participating in pharmacotherapy trials: a literature review","volume":"86","author":"Oelke","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.urology.2018.03.038_bib0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","article-title":"Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis","volume":"69","author":"Vouri","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.urology.2018.03.038_bib0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1185\/03007995.2016.1149806","article-title":"Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics","volume":"32","author":"Wagg","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urology.2018.03.038_bib0095","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int J Clin Pract"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518302954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518302954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T10:23:22Z","timestamp":1531995802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429518302954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":18,"alternative-id":["S0090429518302954"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2018.03.038","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron 25\u2009mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2018.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}